Preliminary Programme

Wednesday, 17 November 2010

SO 0101 How can we neutralise the stigma of the treatment of depression
Jiri Raboch (Czeck Republic)

SO 0102 The need for early onset treatments in depression and anxiety
Carlo A. Altamura (Italy)

SO 0103 Stigma against PMDD caused by regulatory action
Elias Eriksson (Sweden)

16.00 - 16.30 Coffee break

SO 0201 Preclinical work in anxiety: Latest insights
Hans Den Boer (The Netherland)

SO 0202 Concurrent anxiety: Increasing the burden of other psychiatric disorders
Hans Jurgen Moeller (Germany)

SO 0203 Optimizing treatment in the presence of anxiety
Siegfried Kasper (Austria)

Symposium sponsored by an unrestricted educational grant from Pfizer Limited

18.00 - 19.00 Opening Ceremony

THURSDAY, 18 November 2010

SO 0301 Adressing stigma at diagnosis adopting an holistic approach from the outset
TBC

SO 0302 Prioritising safety and efficacy in the treatment of elderly patients
Eva Topinková (Czech Republic)

SO 0303 Is the choice of antidepressant a major factor in attaining the treatment goal?
Stuart Montgomery (UK)

SO 0304 Treatment myths – a panel discussion
Siegfried Kasper (Austria)

Symposium sponsored by an unrestricted educational grant from H. Lundbeck A/S

10.30 - 11.00 Coffee break

SO 0401 Treatment of Parkinsons disease and depression
Cristina Sampaio (Portugal)

SO 0402 Influence of comorbid anxiety disorders on outcome in major depression
David Baldwin (UK)

SO 0403 Pharmacotherapy of neuropsychiatric manifestations of AIDs
Christer Allgulander (Sweden)

12.30 - 13.30 Lunch

SO 0501 Symptom profile and outcome in bipolar and unipolar depression
Jules Angst (Switzerland)

SO 0502 A review of the evidence for monotherapy in bipolar depression
Eduard Vieta (Spain)

SO 0503 Augmentation strategies for bipolar and unipolar depression
Michael Bauer (Germany)

Pro: Zoltan Rhimer (Hungary)
Contra: Karl Broich (Germany)

16.00 - 16.30 Coffee break

SO 0701 Introduction: What is the noradrenergic symptom cluster?
Stuart Montgomery (UK)

SO 0702 The increasing burden of depressive disorder
Jean-Pierre Lépin (France)

SO 0703 The noradrenergic symptom cluster - clinical expression and neuropharmacology
Pierre Blier (Canada)

SO 0704 Improvement of the noradrenergic symptom cluster following treatment with milnacipran
Siegfried Kasper (Austria)

Symposium sponsored by an unrestricted educational grant from Pierre Fabre Medicaments

FRIDAY, 19 November 2010

SO 0801 Resistant depression state or trait: genetic and clinical evidence?
Alessandro Serretti (Italy)

SO 0802 Do current guidelines interfere with identifying and treating resistant depression
Stuart Montgomery (UK)

SO 0803 Advances in the treatment of resistant depression
Daniel Souery (Belgium)

10.30 - 11.00 Coffee break

SO 0901 Multiple treatments meta-analysis of antidepressants for major depression: strengths and weaknesses?
Andrea Cipriani (Italy)

SO 0902 Mixed-treatments comparison meta-analysis of antidepressants: implications for everyday clinical practice
Corrado Barbui (Italy)

SO 0903 Are direct double-blind comparisons the best tests of superiority?
Hans Jurgen Moeller (Germany)

12.30 - 13.30 Lunch

SO 1102 Relevance of cognitive dimensions in the treatment of OCD
Naomi Fineberg (UK)

SO 1103 Do imaging studies improve treatment strategies in OCD?
Damiaan Denys (The Netherlands)